(NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its ...

“If you are developing a drug, for example, for infantile epilepsy ... a patient’s genome impacts their health. Luckily there have been some encouraging developments in sequencing technology ...

GeneDx Corp's 2024 success story: profitability, 100x returns, NICU market expansion, pediatric neurology diagnostics, and ...

Physicians and scientists have long been intrigued by the variety of ways that language can be affected by brain disease. It is clear that epilepsy can affect language, but the extent and nature of ...

Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH.